MA41432A - Composition pharmaceutique pour le traitement de maladies gastro-intestinales - Google Patents

Composition pharmaceutique pour le traitement de maladies gastro-intestinales

Info

Publication number
MA41432A
MA41432A MA041432A MA41432A MA41432A MA 41432 A MA41432 A MA 41432A MA 041432 A MA041432 A MA 041432A MA 41432 A MA41432 A MA 41432A MA 41432 A MA41432 A MA 41432A
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
gastrointestinal
diseases
Prior art date
Application number
MA041432A
Other languages
English (en)
French (fr)
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA41432A publication Critical patent/MA41432A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA041432A 2015-01-30 2016-01-27 Composition pharmaceutique pour le traitement de maladies gastro-intestinales MA41432A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물

Publications (1)

Publication Number Publication Date
MA41432A true MA41432A (fr) 2017-12-05

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041432A MA41432A (fr) 2015-01-30 2016-01-27 Composition pharmaceutique pour le traitement de maladies gastro-intestinales

Country Status (19)

Country Link
EP (1) EP3250199A4 (zh)
JP (1) JP6419347B2 (zh)
KR (2) KR101583452B1 (zh)
CN (1) CN107205947B (zh)
AR (1) AR105413A1 (zh)
CL (1) CL2017001680A1 (zh)
CO (1) CO2017006222A2 (zh)
EA (1) EA032385B9 (zh)
EC (1) ECSP17038599A (zh)
GE (2) GEP20196941B (zh)
MA (1) MA41432A (zh)
MX (1) MX375765B (zh)
MY (1) MY195824A (zh)
PE (1) PE20171340A1 (zh)
PH (1) PH12017550051A1 (zh)
SA (1) SA517382016B1 (zh)
TW (1) TWI635859B (zh)
UA (1) UA116517C2 (zh)
WO (1) WO2016122226A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
ATE213635T1 (de) * 1994-04-26 2002-03-15 Chugai Pharmaceutical Co Ltd Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
JP5516401B2 (ja) * 2008-07-01 2014-06-11 ライオン株式会社 固形内服製剤
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
ECSP17038599A (es) 2017-09-29
KR101583452B1 (ko) 2016-01-11
GEP20196941B (en) 2019-01-10
EA032385B9 (ru) 2019-07-31
EP3250199A4 (en) 2018-08-08
JP6419347B2 (ja) 2018-11-07
KR101583452B9 (ko) 2022-05-02
GEAP201814551A (en) 2018-08-27
CL2017001680A1 (es) 2018-01-12
CN107205947A (zh) 2017-09-26
GEP20186941B (en) 2019-01-10
PH12017550051A1 (en) 2018-01-29
TWI635859B (zh) 2018-09-21
CO2017006222A2 (es) 2017-09-20
CN107205947B (zh) 2020-05-22
MX375765B (es) 2025-03-07
KR20160094268A (ko) 2016-08-09
EA032385B1 (ru) 2019-05-31
TW201639559A (zh) 2016-11-16
WO2016122226A2 (en) 2016-08-04
MX2017007567A (es) 2017-10-19
EA201791458A1 (ru) 2017-11-30
BR112017013857A2 (pt) 2018-02-27
SA517382016B1 (ar) 2021-03-18
JP2018503672A (ja) 2018-02-08
WO2016122226A3 (en) 2016-09-15
EP3250199A2 (en) 2017-12-06
PE20171340A1 (es) 2017-09-13
MY195824A (en) 2023-02-22
AR105413A1 (es) 2017-10-04
UA116517C2 (uk) 2018-03-26

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
EP3436002A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA41449A (fr) Polythérapies pour le traitement de cancers
MA42999A (fr) Polythérapie pour le traitement de malignités
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3474854A4 (en) CANCER TREATMENT COMBINATIONS
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3378484A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CARDIAL FIBROSIS
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP3344325A4 (en) LOCAL ADMINISTRATION OF MEDICAMENTS FOR THE TREATMENT OF ASTHMA
EP3766497A4 (en) Drug for treating cough
EP3288565A4 (en) EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER OR IMMUNE DISEASES
EP3413898A4 (en) USE OF TREHALOSIS TO TREAT NEUROLOGICAL ILLNESSES
EP3373931A4 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
EP3395341A4 (en) COMPOSITION FOR THE TREATMENT OF MOTORURON DISEASES AND USE THEREOF
EP3413882A4 (en) METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEURODE GENERATION